Bailard’s Eledon Pharmaceuticals ELDN Stock Holding History

Bailard’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-27,413	Closed	-$67K	–	695
2022 Q2	$67K	Sell	27,413 -187	-0.7%	-$571	﹤0.01%	668
2022 Q1	$109K	Buy	+27,600	New	+$107K	﹤0.01%	692

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bailard's ELDN Position: Q3 2022 in Review

Bailard sold out of Eledon Pharmaceuticals (ELDN) in Q3 2022, closing a stake of 27,413 shares — an estimated $67K sold.

Bailard first reported a position in ELDN in Q1 2022 and held it in 2 quarters. The position peaked at $109K in Q1 2022. 31 funds tracked by Wall St. Rank hold ELDN as of Q3 2022.

Bailard reported no remaining Eledon Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Bailard sold 27,413 Eledon Pharmaceuticals shares in Q3 2022, an estimated $67K.
Bailard first reported a position in Eledon Pharmaceuticals in Q1 2022 and held it in 2 quarters.
Bailard's Eledon Pharmaceuticals position peaked at $109K in Q1 2022.
31 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.